{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"6"}]}],"title":"Decrease to <60"},{"categories":[{"measurements":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"15"}]}],"title":"Change to normal or no change"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"3"}]}],"title":"Increase to >100"}],"denoms":[{"counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"99"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"description":"Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Number of participants with worst case change from Baseline in pulse rate is presented. Data is categorized as: pulse rate 'decrease to \\<60 beats per minute \\[bpm\\]', 'increase to \\>100 bpm' and 'change to normal or no change'. If values were unchanged (example: increase to \\>100 bpm to increase to \\>100 bpm), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to \\<60 bpm' and 'increased to \\>100 bpm' during post Baseline. Data for worst-case post Baseline is presented.","groups":[{"description":"Participants were administered frozen liquid (30 mg/vial solution in a single use vial) at a dose of 2.5 mg/kg GSK2857916 as IV solution once every three weeks for a maximum of up to 39 cycles (1 cycle= 21 days). Frozen liquid was diluted with 0.9 percent saline.","id":"OG000","title":"Main Study: GSK2857916 2.5 mg/kg (Frozen Liquid)"},{"description":"Participants were administered frozen liquid (30 mg/vial solution in a single use vial) at a dose of 3.4 mg/kg GSK2857916 as IV solution once every three weeks for a maximum of up to 32 cycles (1 cycle= 21 days). Frozen liquid was diluted with 0.9 percent saline.","id":"OG001","title":"Main Study: GSK2857916 3.4 mg/kg (Frozen Liquid)"},{"description":"Participants were administered lyophilized powder (100 mg/vial in a single use vial) at a dose of 3.4 mg/kg GSK2857916 given IV for a maximum of 35 cycles (1 cycle= 21 days). Lyophilized powder was reconstituted using water for injection.","id":"OG002","title":"Main Study: GSK2857916 3.4 mg/kg (Lyophilized)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full Safety Population. 3 participants out of 221 participants did not receive any study treatment and thus, were excluded from the Full Safety Population.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and Up to 186 weeks","title":"Number of Participants With Change From Baseline in Pulse Rate","type":"SECONDARY","unitOfMeasure":"Participants"}